Type I allergy is an immunoglobulin E (IgE)-mediated hypersensitivity disease affecting more than 25% of the population. Currently, diagnosis of allergy is performed by provocation testing and IgE serology using allergen extracts. This process defines allergen-containing sources but cannot identify the disease-eliciting allergenic molecules. We have applied microarray technology to develop a miniaturized allergy test containing 94 purified allergen molecules that represent the most common allergen sources. The allergen microarray allows the determination and monitoring of allergic patients' IgE reactivity profiles to large numbers of disease-causing allergens by using single measurements and minute amounts of serum. This method may change established practice in allergy diagnosis, prevention, and therapy. In addition, microarrayed antigens may be applied to the diagnosis of autoimmune and infectious diseases.
T he hallmark of type I allergy is the production of immunoglobulin E (IgE) antibodies against otherwise harmless antigens, termed allergens, which can originate from a multitude of allergen sources (e.g., mites, plant pollens, animals, insects, molds, and food) (1) . IgE recognition of allergens per se would likely remain unnoticed because IgE represents the least abundant class of immunoglobulins (2, 3) . However, receptor cross-linking on effector cells (i.e., mast cells, basophils) by IgE-allergen complexes triggers the release of biological mediators (e.g., histamine, leukotrienes) within a few minutes and thus causes the immediate symptoms of type I allergy (hay fever, allergic asthma, anaphylactic shock) (4) . In addition, IgE-mediated presentation of allergens to T cells leads to T-cell activation and chronic allergic inflammation (e.g., chronic asthma, atopic dermatitis), particularly after repeated contact with allergens (5) . The latter event also induces increases of allergen-specific serum IgE levels and patients' sensitivity to allergens (6) .
Since 1880 when Charles Blackley performed provocation tests by administrating pollen extracts to his skin (7) , diagnosis of type I allergy has been conducted by provocation testing with extracts prepared from the suspected allergen sources. Almost 90 years later, shortly after the discovery of IgE antibodies, the radioallergosorbent test (RAST) was introduced, which allowed the in vitro measurement of specific serum IgE antibodies by using radioisotope-labeled anti-IgE antibodies (2, 3, 8) . However, until now allergen extracts consisting of variable mixtures of allergenic and nonallergenic components have been used for in vitro and in vivo diagnosis of allergy. With such diagnostic extracts, the allergen sources can be identified but not the molecules that cause disease. For this reason, it is impossible to discriminate with extract-based diagnosis whether a patient is cosensitized to a variety of unrelated allergen molecules in different allergen sources or is cross-sensitized to few, but cross-reactive, allergens. Extractbased diagnosis also cannot provide information regarding the individual reactivity profiles of allergic patients and thus fails to identify the precise target molecules for specific immunotherapy (9) .
Here, we present a novel principle for the diagnosis of type I allergy that allows the simultaneous determination of complex IgE reactivity profiles with purified allergen molecules that have been printed as microarrays on preactivated glass slides. This approach is based on recent advances made in the field of molecular allergology and biochip technology. The application of molecular biology to the field of allergen characterization has led to the availability of a continuously growing number of recombinant allergen molecules that mimick the immunological properties of their natural counterparts (9, 10) . Progress achieved in microchip technology allows precise delivery and immobilization of a great number of nanoliter aliquots of protein samples onto small surfaces, as well as analysis and quantification of interactions with potential ligands (11) (12) (13) (14) .
In this study, we combined the latter two technologies to develop a miniaturized allergy test that is based on microarrayed allergen molecules representative of important allergen sources, and we investigated microchip technology for possible use in the determination of allergic patients' IgE reactivity profiles. Table 1 presents characteristics of the purified allergen molecules used for the allergen microarray in this study. They were selected to represent the most common allergen sources. With the exception of Bos d 2, one Ves v 5 preparation and Pol a 5 (expression in yeast: Pichia pastoris), Api m 2 (expression in baculovirus-infected insect cells), and Mal d 2 (expression in TMV-infected tobacco), all recombinant allergens were expressed in Escherichia coli. Certain allergens were purified from natural allergen sources (e.g., albumins from cat, dog, cattle, mouse, rat, pig, sheep, chicken, rabbit, hamster, horse, pigeon, guinea pig; Phl p 4; Pen a 1; Pen n 13). References and GenBank accession numbers of the allergen molecules are displayed in Table 1 .
MATERIALS AND METHODS

Purified recombinant and natural allergens
Characterization of allergic patients
Serum samples were obtained from 20 allergic patients and, for control purposes, from nonatopic persons. The diagnosis of type I allergy was based on case history, skin prick testing, and IgE serology as described earlier (15, 16) . To evaluate the performance of the microarray, we included patients with various manifestations of allergic disease (e.g., rhinoconjunctivitis, asthma, atopic dermatitis, and food allergy) who exhibited different sensitization spectra (oligosensitization, polysensitization) and who had different total serum IgE levels (28 to >2000 kU/L) ( Table 2) .
Preparation of the microarray of purified allergens
Preactivated glass slides were developed by VBC-GENOMICS (Vienna, Austria). The slides contained an amine-reactive coating optimized by VBC-GENOMICS for the covalent attachment of proteins and assay performance. Purified allergen components were diluted to a final spotting concentration of 0.3 mg/ml in 150 mM sodium phosphate buffer (pH 8.5) containing 0.1% sodium dodecyl sulfate. Allergen solutions were spotted robotically in an ordered array onto the preactivated glass slides by using an Affymetrix 417 Arrayer (Affymetrix, Santa Clara, CA). A 1 µg/ml dilution of labeled anti-IgE antibody was spotted as a guide dot to support automatic image analysis.
Diagnosis of allergy based on microarray, dot blot, and skin test assays
Allergen chips were washed in TBS-T (10 mM Tris-HCl, 150 mM NaCl, 0.5% Tween-20, pH 8.0) for 15 min, rinsed with double-distilled water (H 2 O dd ), and air-dried. Slides were then incubated with 200 µl of patients' serum diluted 1:5 in TBS-T by using Probe-Clip Incubation Press Seal Chambers (Sigma, St. Louis, MO) for 60-180 min at 37°C with shaking at 150 rpm. Slides were then rinsed with TBS-T and washed with TBS-T for another 15 min. Bound IgE antibodies were detected with a 1:1000 diluted mouse monoclonal anti-human IgE antibody (Pharmingen, San Diego, CA), which had been labeled by using the Alexa Fluor 546 proteinlabeling kit according to the manufacturer's protocol to approximately 5.53 mol dye/mol protein.
Slides were washed five times in TBS-T, rinsed with H 2 O dd , and air-dried. Allergen arrays were scanned by using an Affymetrix 418 scanner (Affymetrix), with the laser power and PMT gain set to 100%. Data were evaluated with the GenePix Software Version 3.0 (Axon Instruments, Union City, CA) and Microsoft Excel. The mean signal of each triplicate determination was considered positive when it was at least five times higher than the signal obtained for spotted human serum albumin. The latter was usually not higher than signals obtained for buffer dots.
In parallel to the microarray, IgE reactivity to nitrocellulose-dotted allergen molecules was analyzed for each serum sample. Aliquots of 2 µl containing 100 ng of each allergen were dotted to nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany) and probed with 1:5 serum dilutions from the allergic patients and nonatopic persons as described earlier. Bound IgE antibodies were detected with 125 I-labeled anti-human IgE antibodies (RAST, Pharmacia, Uppsala, Sweden) (17).
Skin prick tests were performed with 20-µl aliquots of purified allergens diluted in H 2 O dd to final concentrations of 20 µg/ml, with test areas on the backs of selected atopic persons, as described previously (18) . No skin tests were performed with purified natural albumins. For control purposes, prick tests were performed with diluent (H 2 O dd ) alone and histamine (1 mg/ml) (Allergopharma, Reinbek, Germany).
RESULTS
Selection, purification, and characterization of allergen molecules
We purified 78 recombinant and 16 natural allergen molecules representative of most of the important allergen sources (Table 1) . Allergen molecules that according to IgE competition studies resemble the epitope complexity of tree (birch), grass (timothy grass), and weed pollens were prepared as described before (15, 16) . We also produced recombinant mite, animal, mold, insect, food, and latex allergens and one autoallergen according to the protocols described in the supplementary references for Table 1 (19) (20) (21) (22) (23) (24) (25) (26) . Purified allergen components that remained soluble in aqueous solutions up to a concentration of approximately 1 mg/ml were obtained for most allergens.
Microarrayed allergen molecules allow the determination of IgE reactivity profiles of allergic patients
The allergen components were microarrayed as triplicates onto preactivated glass slides in groups representing individual allergen sources (Fig. 1a, Table 1 ). For certain allergens, several recombinant protein preparations were immobilized (e.g., Der p 2: mite; Fel d 1: cat) (Fig. 1a , Table 1 ). Microarrayed allergen components were then exposed to serum samples from allergic patients who were sensitized against a broad variety of different allergen sources and who exhibited total serum IgE levels ranging between 28 and higher than 2000 kU/L ( Table 2) . Only a small amount of serum (40 µl) from each patient was needed to test IgE reactivity to almost 100 allergen triplicates in a single test, whereas most currently used diagnostic tests require 50 µl of serum for testing of IgE reactivity to one single component or extract.
To examine the performance of the allergen microarray, several control experiments were performed. First, individual allergen components were printed as triplicates to assay for homogeneity of the spotting process. Second, sera were assayed three times on individually printed allergen arrays to determine the reproducibility of the microarray-based allergy test system. The mean Pearson correlation coefficient calculated from these experiments was >0.95. Figure 1b and c exemplifies the overall performance of the allergen array. The polysensitized patient A showed IgE reactivity to microarrayed allergen components consistent with the clinical sensitization profile (Fig. 1b, Table 2 ), whereas the nonatopic person's serum (Fig. 1c) did not react with any of the immobilized allergen components. Both microarrays shown in Fig. 1b and c contained comparable amounts of immobilized labeled anti-human IgE antibodies. As exemplified by patient A, we found that the IgE reactivity profiles determined with the allergen microarrays were in good agreement with those determined by skin prick testing or with allergen components that had been spotted onto nitrocellulose under conditions of allergen excess (0.2 µg/spot) (Fig. 1b, d, e) .
Microarray-based allergy diagnosis reflects the clinical sensitization pattern of patients
To evaluate the allergen microarray, we tested serum from patients who were allergic to various numbers of different allergen sources and who showed low serum IgE levels (<100 kU/L) (patients F, I, Q, S, T), medium serum IgE levels (100-500 kU/L) (patients C, E, G, K, M, O, P, R), and high serum IgE levels (>500 kU/L) (patients A, B, D, H, J, L, N) ( Table 2 ). We found that clinical sensitivity to the different allergen sources was well reflected by the IgE reactivity profile to the microarrayed allergen components from the respective sources, e.g., patient A with sensitivity to birch, grass pollen, animal dander, mites, and molds reacted with the following allergens: recombinant birch (Bet v 1), grass pollen (Phl p 1, Phl p 2, Phl p 5, Phl p 6), mite (Der p 2, Lep d 13, Eur m 2.0101), insect (Plo i 1), animal (cat: Fel d 1, albumins from various animals), and yeast (Mal f 5) ( Table 2 , Fig. 1a, b) . Likewise, we found that an atopic patient with allergic bronchopulmonary aspergillosis reacted with several of the recombinant Aspergillus allergens (patient N, Table 2 ). However, in agreement with previously reported results on skin prick and RAST testing (27), we observed no strict association between the magnitude of the wheal reactions (i.e., mean wheal diameters) in skin prick testing and the fluorescence intensity as measured in the microarray-based IgE detection system (data not shown).
DISCUSSION
In this study, we present a novel principle for the diagnosis of type I allergy with purified allergens printed as microarrays on preactivated glass slides (Fig. 2) . Allergen molecules representing important allergen sources were produced as recombinant proteins or, in certain cases, purified as natural proteins (Fig. 2, parts 1 and 2) . The purified allergen molecules were then microarrayed on preactivated glass slides to obtain allergen chips that allow the determination of patients' IgE reactivity profiles with minute amounts of serum in single tests (Fig. 2, parts 3-5) . A major difference between the allergen microarray described and current allergy tests is that the microarray contains defined allergen molecules as reactants, whereas currently used tests are based on allergen extracts consisting of mixtures of allergenic as well as nonallergenic molecules. Thus, the latter do not allow identification of the disease-eliciting molecules.
Because IgE antibodies are present in serum in only trace amounts, detection of IgE antibodies specific for microarrayed allergen components represented a major challenge for the application of protein chip technology to the field of allergy diagnosis. Nevertheless, we found that a single fluorescence-labeled monoclonal anti-human IgE antibody allowed the detection of IgE reactivities to immobilized allergens in serum samples containing high or low total IgE levels as well as allergen-specific IgE levels (Fig. 1b, Table 2 ). We also obtained comparable results over a range of several serum dilutions (undiluted, 1:2, 1:5, 1:10) that are commonly applied in various established IgE detection systems (RAST, ELISA, immunoblot) (data not shown).
Current allergen test systems utilize very high amounts of allergen extracts that are tested separately to obtain maximal sensitivity. In contrast, the allergen microarray is based on the simultaneous exposure of rather low amounts of purified allergens to serum IgE, but the obtained results were comparable to those of RAST-based tests. It may even be argued that the principle of simultaneous multiallergen testing more closely mimicks the natural exposure to a variety of tiny amounts of allergen molecules that occurs in allergic patients. Nevertheless, it will be possible to increase the sensitivity of the allergen microarray by using a mixture of different monoclonal anti-human IgE antibodies for the detection of bound IgE antibodies or by other amplifying techniques (e.g., rolling circle DNA amplification) (28).
Compared with currently used extract-based serological diagnosis, the recombinant allergenbased microarray offers many fundamental advantages. It allows the detection of specific IgE reactivities to defined allergen components and thus the precise identification of the diseaseeliciting allergens. The IgE reactivity profile to a great number of different allergen molecules can be analyzed in a single and fast determination. Furthermore, only small amounts of serum are required, making the allergen microarray particularly useful for the determination of complex IgE reactivity profiles when it is difficult to obtain large amounts of serum from patients (e.g., for the monitoring of the onset and development of type I allergy in early childhood).
It will be certainly necessary to add additional molecules or epitopes to the panel of purified allergen components established in our study to cover the full spectrum of all important allergen sources and to accommodate the sensitization profiles of different populations of patients. The latter will not represent a major problem because the number of available recombinant allergen molecules is rapidly increasing. Furthermore, the glass slides used for the production of allergen arrays can in principle accommodate several thousands of individual components and therefore could include a large number of additional allergen molecules and, perhaps, even allergen epitopes. One of the advantages of allergen microarrays used for diagnostic purposes is, therefore, that their allergen or epitope repertoire can be continuously expanded and improved depending on the availability of newly isolated components. Microarrays will allow the monitoring of the IgE reactivity profiles during the development and course of the disease as well as during treatment, and they will also allow correlation of eventual changes of the reactivity profiles with clinical parameters (e.g., progression of the allergic rhinoconjunctivitis to asthma, or development of clinical sensitivity to additional allergen sources).
By using specific antibody probes to immunoglobulin classes or subclasses other than IgE, it will be possible to study in detail the allergen and epitope recognition by antibodies that may compete with IgE and to evaluate their possible protective role. On the basis of the precise IgE reactivity profile determined by allergen microarrays, it will be possible to improve the selection of currently available forms of therapy as well as to develop new allergen-specific therapeutic strategies. In this context, it is noteworthy that for several important allergens, derivatives have been produced by recombinant DNA and synthetic peptide technology that exhibited a greatly reduced allergenic activity and that may be used to improve the safety and efficacy of allergenspecific immunotherapy (29, 30) . It is therefore likely that microarrayed allergen components will fundamentally change the current practice of allergy diagnosis, prevention, and therapy. In addition, the principle of component-resolved diagnosis based on microarrayed purified antigens may find application to autoimmune and infectious diseases.
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